These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 21342124)
1. Nanoparticulate drug delivery in pregnancy: placental passage and fetal exposure. Menezes V; Malek A; Keelan JA Curr Pharm Biotechnol; 2011 May; 12(5):731-42. PubMed ID: 21342124 [TBL] [Abstract][Full Text] [Related]
2. Dynamic placenta-on-a-chip model for fetal risk assessment of nanoparticles intended to treat pregnancy-associated diseases. Shojaei S; Ali MS; Suresh M; Upreti T; Mogourian V; Helewa M; Labouta HI Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166131. PubMed ID: 33766738 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic and safety considerations of nanoparticle-mediated drug delivery in pregnancy. Keelan JA; Leong JW; Ho D; Iyer KS Nanomedicine (Lond); 2015 Jul; 10(14):2229-47. PubMed ID: 26214358 [TBL] [Abstract][Full Text] [Related]
4. Current understanding of the toxicological risk posed to the fetus following maternal exposure to nanoparticles. Zhang Y; Wu J; Feng X; Wang R; Chen A; Shao L Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1251-1263. PubMed ID: 29086601 [TBL] [Abstract][Full Text] [Related]
5. Barrier capacity of human placenta for nanosized materials. Wick P; Malek A; Manser P; Meili D; Maeder-Althaus X; Diener L; Diener PA; Zisch A; Krug HF; von Mandach U Environ Health Perspect; 2010 Mar; 118(3):432-6. PubMed ID: 20064770 [TBL] [Abstract][Full Text] [Related]
6. Exploiting the placenta for nanoparticle-mediated drug delivery during pregnancy. Figueroa-Espada CG; Hofbauer S; Mitchell MJ; Riley RS Adv Drug Deliv Rev; 2020; 160():244-261. PubMed ID: 32956719 [TBL] [Abstract][Full Text] [Related]
7. Relevance to investigate different stages of pregnancy to highlight toxic effects of nanoparticles: The example of silica. Pietroiusti A; Vecchione L; Malvindi MA; Aru C; Massimiani M; Camaioni A; Magrini A; Bernardini R; Sabella S; Pompa PP; Campagnolo L Toxicol Appl Pharmacol; 2018 Mar; 342():60-68. PubMed ID: 29407774 [TBL] [Abstract][Full Text] [Related]
8. Demonstration of the clathrin- and caveolin-mediated endocytosis at the maternal-fetal barrier in mouse placenta after intravenous administration of gold nanoparticles. Rattanapinyopituk K; Shimada A; Morita T; Sakurai M; Asano A; Hasegawa T; Inoue K; Takano H J Vet Med Sci; 2014 Mar; 76(3):377-87. PubMed ID: 24257253 [TBL] [Abstract][Full Text] [Related]
9. The role of the placenta in thyroid hormone delivery to the fetus. Chan SY; Vasilopoulou E; Kilby MD Nat Clin Pract Endocrinol Metab; 2009 Jan; 5(1):45-54. PubMed ID: 19079273 [TBL] [Abstract][Full Text] [Related]
10. Surface-Functionalized Nanoparticles as Efficient Tools in Targeted Therapy of Pregnancy Complications. Zhang B; Liang R; Zheng M; Cai L; Fan X Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31349643 [TBL] [Abstract][Full Text] [Related]
12. Maternal-to-fetal transfer of 5-methyltetrahydrofolate by the perfused human placental cotyledon: evidence for a concentrative role by placental folate receptors in fetal folate delivery. Henderson GI; Perez T; Schenker S; Mackins J; Antony AC J Lab Clin Med; 1995 Aug; 126(2):184-203. PubMed ID: 7636392 [TBL] [Abstract][Full Text] [Related]
13. Leptin distribution and metabolism in the pregnant rat: transplacental leptin passage increases in late gestation but is reduced by excess glucocorticoids. Smith JT; Waddell BJ Endocrinology; 2003 Jul; 144(7):3024-30. PubMed ID: 12810558 [TBL] [Abstract][Full Text] [Related]
14. Perfusion studies of glyburide transfer across the human placenta: implications for fetal safety. Kraemer J; Klein J; Lubetsky A; Koren G Am J Obstet Gynecol; 2006 Jul; 195(1):270-4. PubMed ID: 16579925 [TBL] [Abstract][Full Text] [Related]
15. Effects of gestational age and surface modification on materno-fetal transfer of nanoparticles in murine pregnancy. Yang H; Sun C; Fan Z; Tian X; Yan L; Du L; Liu Y; Chen C; Liang XJ; Anderson GJ; Keelan JA; Zhao Y; Nie G Sci Rep; 2012; 2():847. PubMed ID: 23150793 [TBL] [Abstract][Full Text] [Related]
16. Development of a Pharmacokinetic Model of Transplacental Transfer of Metformin to Predict In Vivo Fetal Exposure. Kurosawa K; Chiba K; Noguchi S; Nishimura T; Tomi M Drug Metab Dispos; 2020 Dec; 48(12):1293-1302. PubMed ID: 33051249 [TBL] [Abstract][Full Text] [Related]
17. Maternal-fetal transfer of endocrine disruptors in the induction of Calbindin-D9k mRNA and protein during pregnancy in rat model. Hong EJ; Choi KC; Jeung EB Mol Cell Endocrinol; 2003 Dec; 212(1-2):63-72. PubMed ID: 14654251 [TBL] [Abstract][Full Text] [Related]
18. Nanomedicines: An approach to treat placental insufficiency and the current challenges. van Kammen CM; van Woudenberg SJ; Schiffelers R; Terstappen F; Lely AT J Control Release; 2023 Aug; 360():57-68. PubMed ID: 37330012 [TBL] [Abstract][Full Text] [Related]
19. Distribution of saquinavir, methadone, and buprenorphine in maternal brain, placenta, and fetus during two different gestational stages of pregnancy in mice. Coles LD; Lee IJ; Hassan HE; Eddington ND J Pharm Sci; 2009 Aug; 98(8):2832-46. PubMed ID: 19116954 [TBL] [Abstract][Full Text] [Related]
20. [Mechanisms of drug metabolism in the feto-placental system]. Aĭlamazian EK; Korkhov VV Akush Ginekol (Mosk); 1990 Mar; (3):11-3. PubMed ID: 2197887 [No Abstract] [Full Text] [Related] [Next] [New Search]